Is it Time to Dump IGM Biosciences Inc (IGMS) Stock After it Is Up 7.01% in a Week?

The market has been down on IGM Biosciences Inc (IGMS) stock recently. IGMS gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

IGM Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IGMS!

See Full IGMS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IGMS Stock Today?

IGM Biosciences Inc (IGMS) stock is trading at $4.73 as of 1:26 PM on Thursday, Nov 2, a rise of $0.53, or 12.62% from the previous closing price of $4.20. The stock has traded between $4.27 and $4.84 so far today. Volume today is below average. So far 231,517 shares have traded compared to average volume of 338,496 shares.

More About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Click Here to get the full Stock Report for IGM Biosciences Inc stock.